Patents by Inventor Ali Fattaey
Ali Fattaey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180133223Abstract: The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: November 1, 2017Publication date: May 17, 2018Inventors: Ali Fattaey, Garrett W. Rhyasen
-
Publication number: 20090215711Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: April 30, 2004Publication date: August 27, 2009Applicant: Sagres Discovery, Inc.Inventors: David W. Morris, Marc S. Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Publication number: 20090214546Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: April 27, 2005Publication date: August 27, 2009Inventors: David W. Morris, Marc S. Malandro, Albert Lai, Chistin Tse, Ali Fattaey
-
Publication number: 20080299561Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: December 21, 2007Publication date: December 4, 2008Inventors: David W. Morris, Marc S. Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Patent number: 7396679Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.Type: GrantFiled: November 25, 2002Date of Patent: July 8, 2008Assignee: Onyx Pharmaceuticals, Inc.Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Yuqiao Shen, Sylvie Laquerre
-
Patent number: 7332281Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: GrantFiled: April 27, 2004Date of Patent: February 19, 2008Assignee: Sagres Discovery, Inc.Inventors: David W. Morris, Marc S. Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Publication number: 20070042385Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: February 23, 2005Publication date: February 22, 2007Inventors: David Morris, Marc Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Publication number: 20060194210Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: April 27, 2004Publication date: August 31, 2006Inventors: David Morris, Marc Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Patent number: 7078030Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.Type: GrantFiled: December 11, 2003Date of Patent: July 18, 2006Assignee: Onyx Pharmaceuticals, IncInventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Jerry Yuqiao Shen, Sylvie Laquerre
-
Patent number: 7001596Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.Type: GrantFiled: November 14, 2000Date of Patent: February 21, 2006Assignee: Onyx Pharmaceuticals, Inc.Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston
-
Publication number: 20060024677Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: July 20, 2004Publication date: February 2, 2006Inventors: David Morris, Marc Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Publication number: 20040241142Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.Type: ApplicationFiled: December 11, 2003Publication date: December 2, 2004Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Jerry Yuqiao Shen, Sylvie Laquerre
-
Publication number: 20040151696Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.Type: ApplicationFiled: November 25, 2002Publication date: August 5, 2004Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Yuqiao Shen, Sylvie Laquerre
-
Publication number: 20030186881Abstract: Compositions of matter consisting of a family of related nucleic acid sequences that encode proteins, termed Cell Growth Regulatory Proteins, that phosphorylate cell cycle targets, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the Cell Growth Regulatory Proteins have an apparent molecular weight of about 54.6 kdaltons.Type: ApplicationFiled: May 6, 2003Publication date: October 2, 2003Inventors: Robert N. Booher, Ali Fattaey
-
Patent number: 6558918Abstract: Compositions of matter consisting of a family of related nucleic acid sequences that encode proteins, termed Cell Growth Regulatory Proteins, that phosphorylate cell cycle targets, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the Cell Growth Regulatory Proteins have an apparent molecular weight of about 54.6 kdaltons.Type: GrantFiled: October 15, 1997Date of Patent: May 6, 2003Assignee: Onyx Pharmaceuticals, Inc.Inventors: Robert N. Booher, Ali Fattaey
-
Publication number: 20030021768Abstract: Oncolytic viruses are described that have favorable anti-cancer activity and that are produced by random mutagenesis and subsequent bio-selection on cancer cells wherein the viruses are preferably adenoviruses having at least one mutation in the i-leader sequence of the viral major late transcriptional unit.Type: ApplicationFiled: July 9, 2002Publication date: January 30, 2003Inventors: Yuqiao Shen, Terry Hermiston, Ali Fattaey
-
Patent number: 6498163Abstract: This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula I: and Formula II: where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and Z is carboxy. This invention also provides pharmaceutical formulations comprising a compound of Formula I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.Type: GrantFiled: August 2, 1999Date of Patent: December 24, 2002Assignee: Warner-Lambert CompanyInventors: Diane Harris Boschelli, Annette Marian Doherty, Ali Fattaey, David William Fry, Susanne Andrea Trumpp-Kallmeyer, Zhipei Wu, Ellen Myra Dobrusin, Mark Robert Barvian
-
Patent number: 6391630Abstract: Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting of a first polynucleotide sequence that encodes a reporter molecule and a second p53 binding polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.Type: GrantFiled: March 1, 1999Date of Patent: May 21, 2002Assignee: Onyx Pharmaceuticals, Inc.Inventor: Ali Fattaey
-
Patent number: 5876711Abstract: Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting of a first polynucleotide sequence that encodes a reporter molecule and a second p53 binding polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.Type: GrantFiled: May 31, 1996Date of Patent: March 2, 1999Assignee: Onyx Pharmaceuticals, Inc.Inventor: Ali Fattaey